Getein Biotech(SH:603387)2023-04-26 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.66% compared to the same period last year[2] - Net profit attributable to shareholders was ¥121,526,036.35, down 44.44% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥100,536,845.57, a decline of 54.32%[2] - Basic and diluted earnings per share were both ¥0.24, down 44.19% from the previous year[2] - Total operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.7% compared to ¥570,715,217.73 in Q1 2022[18] - Net profit for Q1 2023 was ¥124,371,119.11, a decline of 43.7% from ¥220,693,233.53 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥124,267,374.11, down from ¥220,693,233.53 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was ¥13,484,563.45, representing a significant drop of 79.84%[2] - In Q1 2023, the cash inflow from operating activities was CNY 528,041,082.97, a decrease of 21.1% compared to CNY 669,337,060.24 in Q1 2022[22] - The net cash flow from operating activities was CNY 13,484,563.45, down 79.9% from CNY 66,898,060.91 in the same period last year[22] - Cash inflow from investment activities totaled CNY 186,730,257.77, significantly up from CNY 42,531,695.56 in Q1 2022[22] - The net cash flow from investment activities was CNY 103,596,691.92, compared to a negative CNY 15,619,831.84 in Q1 2022[22] - Cash inflow from financing activities was CNY 297,813,000.00, down from CNY 376,609,940.27 in the previous year[23] - The net cash flow from financing activities was negative CNY 26,790,759.52, a decline from positive CNY 51,380,646.72 in Q1 2022[23] - The ending balance of cash and cash equivalents was CNY 732,976,882.93, down from CNY 1,045,222,484.13 at the end of Q1 2022[23] - The company reported a cash increase of CNY 88,332,104.53 in Q1 2023, compared to CNY 100,071,255.50 in Q1 2022[23] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,671,973,340.42, a slight decrease of 0.15% from the end of the previous year[3] - The company's total liabilities as of Q1 2023 amounted to ¥892,257,607.28, a decrease from ¥1,012,840,595.85 in the previous period[17] - The total equity attributable to shareholders was ¥2,603,189,418.94, an increase from ¥2,482,468,375.18 year-over-year[17] - Shareholders' equity attributable to the parent company increased by 4.86% to ¥2,603,189,418.94 compared to the end of the previous year[3] Revenue Breakdown - The decline in revenue was primarily attributed to a decrease in COVID-related business compared to the previous year[6] - In Q1 2023, the company achieved a revenue of 23.52 million RMB from COVID-related business, a significant decline of 93.11% year-on-year[10] - Excluding COVID revenue, the company's self-produced products generated a total revenue of 286.28 million RMB, marking a year-on-year increase of 71.69%[10] - The POCT product line reported a revenue of 213.16 million RMB, reflecting a year-on-year growth of 56.21%[11] - The sales revenue from the chemical luminescence product line reached 43.18 million RMB, showing a substantial increase of 277.64% year-on-year[11] Research and Development - The company continues to focus on R&D, aiming to enhance competitiveness across its IVD product lines[12] - Research and development expenses for Q1 2023 were ¥55,164,547.70, up from ¥50,924,275.03 in Q1 2022, indicating a focus on innovation[18] - The company plans to accelerate the market validation and coverage of the newly launched Metis6000 fully automated immunoassay line[11] Shareholder Information - The company had a total of 38,070 common shareholders at the end of the reporting period[8]